Rafael L. Perez

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

Luca Richeldi, Evans R. Fernández Pérez, Ulrich Costabel et al. · The Lancet Respiratory Medicine · 2019 · 286 citations

Medicine, Clinical Sciences, Pharmacotherapy +13

The Effects of Chronic Alcohol Abuse on Pulmonary Glutathione Homeostasis

Marc Moss, David M. Guidot, MONIQUE WONG-LAMBERTINA et al. · American Journal of Respiratory and Critical Care Medicine · 2000 · 210 citations

Medicine, Pharmacology, Toxicology +15

Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial

Peter Vink, Josep Ramón, Ana Sánchez‐Fructuoso et al. · Clinical Infectious Diseases · 2019 · 194 citations · Full text

Medicine, Immunology, Nephrology +15

Fibrin enhances the expression of IL-1 <i>beta</i> by human peripheral blood mononuclear cells. Implications in pulmonary inflammation.

Rafael L. Perez, Jesse Roman · The Journal of Immunology · 1995 · 155 citations · Full text

Life Sciences, Cell Biology, Immunology +17

Time-Dependent Changes of Inflammatory Mediators in the Lungs of Humans Exposed to 0.4 ppm Ozone for 2 hr: A Comparison of Mediators Found in Bronchoalveolar Lavage Fluid 1 and 18 hr after Exposure

Robert B. Devlin, William F. McDonnell, Susanne Becker et al. · Toxicology and Applied Pharmacology · 1996 · 132 citations

Veterinary Medicine, Physiology, Toxicology +16